PHOENIX, April 10,
2023 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES,
"SenesTech" or the "Company"), (www.senestech.com) the rodent
fertility control experts and inventors of the only EPA registered
contraceptive for male and female rats, ContraPest®,
today confirmed that the County of Los
Angeles is continuing and expanding its use of fertility
control in the form of ContraPest in current requests for
In January 2022, Los Angeles County issues a Request for
Proposal (RFP) mandating that EPA-registered fertility control be
included in a pest management proposal. As SenesTech's ContraPest
is the only EPA registered fertility control product for rats, this
was a promising endorsement of ContraPest.
After a year's monitored use by the winning bidder, the contract
was renewed. Furthermore, additional RFPs were issued also
mandating the use of EPA registered fertility control.
As part of the RFP process, recently there was a "Job Walk
Question and Answer" segment, where potential bidders could ask
questions and the county would answer them. Among the questions and
answers, were these statements by the county:
- Question: Contrapest is the only current liquid rat
infertility bait. Contrapest is a relatively new product and is not
always successful as rats are neophobic by nature.
We have had very successful results with ContraPest at Baldwin Park. Baldwin Park data showed a 50% reduction in
the population within 6 months. At 12 months Baldwin was at
- Question: We also need to consider the chance the
rats do not take the bait.
Our experience is that ContraPest is very palatable and desirable.
The mere fact that when the bait runs out, the rats continue to eat
the tank, as well as the feeding trough.
- Question: It seems the non-fatal method is not practical for
your expectations. Would fatal methods be considered at
We disagree and believe non-fatal is actually practical and much
"This is what we are hearing more and more, from those who have
incorporated ContraPest into their integrated pest management
programs. Adding ContraPest to the program improves the outcome,
and this has been repeatedly proven," said Joel Fruendt, SenesTech's CEO.
"We knew that the initial project had the potential for
expansion throughout the county. The renewal and expansion was
clearly driven by the success of the deployment. It is also worth
noting that there were only a couple of bidders for the first RFP a
year ago… but from the calls we have received from PMPs about this
latest RFP, it looks like there are ten or so bidding, and many of
them are now considering ContraPest for their other projects,"
continued Mr. Fruendt.
"Part of our selling strategy is to get the customer to specify
fertility control, which then creates instant credibility for the
pest managers seeking their business," concluded Mr. Fruendt.
We are the experts in rat fertility
control. Our passion is to create a healthy environment by better
controlling rat pest populations. We keep an inescapable truth in
mind. Two rats and their descendants can be responsible for the
birth of up to 15,000 pups after a year. We invented ContraPest,
the only U.S. EPA registered contraceptive for male and female
rats. ContraPest fits seamlessly into all integrated pest
management programs, greatly improving the overall goal of
effective rat management. We strive for clean cities, efficient
businesses, and happy households – with a product that was designed
to be effective and sustainable without killing rats. At
SenesTech, we are committed to improving the health of the world by
humanely managing animal populations through fertility control.
For more information visit https://senestech.com/ and
Safe Harbor Statement
This press release contains
"forward-looking statements" within the meaning of federal
securities laws, and we intend that such forward-looking statements
be subject to the safe harbor created thereby. Forward-looking
statements may describe future expectations, plans, results or
strategies and are often, but not always, made through the use of
words such as "believe," "may," "future," "plan," "will," "should,"
"expect," "anticipate," "eventually," "project," "estimate,"
"continuing," "intend" and similar words or phrases. You are
cautioned that such statements are subject to risks, uncertainties
and other factors that could cause actual results to differ
materially from those reflected by such forward-looking statements.
Such factors include, among others, the impacts and implications of
the COVID-19 pandemic, the successful commercialization of our
products, market acceptance of our products, regulatory approval
and regulation of our products and other factors and risks
identified from time to time in our filings with the Securities and
Exchange Commission, including our Annual Report on Form 10-K for
the fiscal year ended December 31,
2022. All forward-looking statements contained in this press
release speak only as of the date on which they were made and are
based on management's assumptions and estimates as of such date.
Except as required by law, we do not undertake any obligation to
publicly update any forward-looking statements, whether as a result
of the receipt of new information, the occurrence of future events
Investors: Robert Blum, Joe
Dorame, Joe Diaz, Lytham Partners, LLC,
Press: Nicole Williams, Chief
Revenue Officer, SenesTech, Inc., 928-779-4143
Company: Tom Chesterman, Chief Financial Officer,
View original content to download
SOURCE SenesTech, Inc.